
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Allogeneic Mesenchymal Stromal Cell
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Recipient : Stempeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Medinet Japan, Stempeutics India Sign License Deal for Stempeucel in Japan
Details : Through the licensing deal, Allogeneic Mesenchymal Stromal Cell will be utilized to address Chronic Limb Threatening Ischaemia Disease (CLTI).
Product Name : Stempeucel
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
October 27, 2025
Lead Product(s) : Allogeneic Mesenchymal Stromal Cell
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Recipient : Stempeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
